Market Newsdesk

• Joint transaction led by Ospraie Management LLC.

• The partnership will immediately leverage their combined technologies and relationships to produce and market sustainable ingredients with increasing protein concentration levels and nutritional characteristics for pet food, aquaculture and animal feed markets globally.
• The partnership will also help accelerate the installation of Ultra-High Protein technology across Green Plains’ platform, amplify its production capabilities and further expand product offerings to accelerate the growth of Optimal Aquafeed’s precision aquaculture solutions, leveraging previously announced partnerships with Novozymes and Hayashikane.
• Fluid Quip’s solutions have been deployed worldwide including
  full technology design, process optimization, yield improvement technologies, new co-product technologies and turnkey capital projects. In addition to protein technologies, the company has launched seven new ag-technology systems in the last seven years that are being used in corn dry milling and bio-chemical production facilities today.
• Green Plains will look to deploy a number of Fluid Quip’s advancing technologies in sustainable high proteins, renewable corn oil and Clean Sugar Technology (CST
  
  ^TM
  
  ) throughout its platform beginning in 2021.
• The partnership will enhance Fluid Quip’s ability to provide premier technologies and engineering services while accelerating technology development and deployment across biofuels and biochemical facilities worldwide.

OMAHA, Neb., Jan. 05, 2021 (GLOBE NEWSWIRE) — Green Plains Inc. (NASDAQ:GPRE), today announced that it has acquired a majority interest in Fluid Quip Technologies (Fluid Quip) in a joint transaction led by Ospraie Management LLC (Ospraie). The acquisition capitalizes on the core strengths of the partners to develop and implement proven, value-added agriculture, food and industrial biotechnology systems, and to rapidly expand installation of Ultra-High Protein production across Green Plains’ facilities in parallel with offering these technologies to partnering biofuel facilities. The terms of the transaction were not disclosed. As part of the transaction, Ospraie acquired 550,000 warrants for Green Plains stock (each warrant equal to one share of stock) with a strike price of $22 per share.

“We believe the Fluid Quip IP portfolio has many game changing valuable technologies that the world needs right now,” said Dwight Anderson, managing partner of Ospraie. “Whether it’s their clean sugar patent suite that creates new, low cost carbohydrate sources for potential use in synthetic biology, food production, or industrial biochemical fermentation, or their patent library on creating high protein ingredients for pet food, aquaculture and other high value feed products, this all improves the environmental impact of feed solutions using inputs from farmers. Sustainable protein solutions are healthier, more efficient and less harmful to the global food system including, reducing the carbon footprint of production agriculture.”

“The partnership between Fluid Quip, Ospraie, and Green Plains will accelerate our path to our 2023 transformation from a commodity-processing business to a value-add agriculture, food technology and industrial biotechnology company focusing on creating diverse, non-cyclical, higher margin products while improving the environmental and carbon footprint of food and feed,” said Todd Becker, president and chief executive officer of Green Plains. “This partnership will help advance the installation of Ultra-High Protein technology across our platform, significantly increase our renewable corn oil production to participate in the growing low carbon fuel markets and the renewable diesel value chain, further drive reduction of our operating expenses and significantly expand our product offerings. This transaction is a vital step in our evolution as it enhances our intellectual property portfolio, deepens our engineering expertise and maximizes operational efficiencies through powerful technology capabilities, while achieving significant financial return opportunities for our shareholders.”

“This transaction offers a unique opportunity to bolster Fluid Quip’s growth trajectory and financial strength through Ospraie’s and Green Plains’ expanded footprint, industry experience and worldwide relationships,” said John Kwik, partner of Fluid Quip Technologies. “We will now be able to accelerate the development of revolutionary technologies that will drive transformational change to how agricultural products get used. With growing interest in the protein space, this partnership will leverage strong capabilities to help defend and protect the Fluid Quip IP portfolio from infringement. Finally, we will continue the implementation of our market leading flex-plant patented technologies, value added protein technologies and bolt-on processes that increase plant efficiencies for Fluid Quip’s large global customer base as well.”

“When you combine all of our partnerships into one innovation and financial engine with the rapid advancements that are already taking place, we believe the results will be truly revolutionary,” stated Becker. “Through this combination, we believe we are squarely positioned to deliver unmatched value as a leader in sustainable, nutritious products created through fermentation of renewable resources using a full suite of world-class technologies.”

Over the last two years, Green Plains has made strategic investments to significantly transform the business from an ethanol and commodities processor, to a leading technology focused, innovative producer of sustainable, value-added ingredient solutions. The partnership will retain all Fluid Quip employees.

About Green Plains Inc.

Green Plains Inc. (NASDAQ:GPRE) is a leading biorefining company focused on the development and utilization of fermentation, agricultural and biological technologies in the processing of annually renewable crops into sustainable value-added ingredients. This includes the production of cleaner low carbon biofuels, renewable feedstocks for advanced biofuels and high purity alcohols for use in cleaners and disinfectants. Green Plains is an innovative producer of Ultra-High Protein and novel ingredients for animal and aquaculture diets to help satisfy a growing global appetite for sustainable protein. The Company also owns a 48.9% limited partner interest and a 2.0% general partner interest in Green Plains Partners LP. For more information, visit www.gpreinc.com.

About Fluid Quip Technologies

Fluid Quip Technologies® (Fluid Quip) provides custom technologies and engineering services to biofuel and biochemical industries worldwide. Fluid Quip’s capabilities include process optimization, yield improvement technologies, advanced co-product technologies and turnkey capital projects. Fluid Quip has commercialized multiple patented and patent-pending technologies to enhance the base corn-to-ethanol dry grind process, create new and novel alternative feed products, and supply the growing need for carbohydrate feed-stocks into the biochemical market. For more information, visit www.fluidquiptechnologies.com.

About Ospraie Management, LLC

Ospraie Management, LLC (Ospraie), was established an independent firm in 2004. Ospraie is an asset management firm that actively invests in commodity markets and basic industries worldwide.

Green Plains Inc. Contacts

Investors: Phil Boggs | Senior Vice President, Investor Relations | 402.884.8700 | [email protected]
Media: Leighton Eusebio | Manager, Public Relations | 402.952.4971 | [email protected]

MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) — iMedia Brands, Inc. (the “Company”) (Nasdaq: IMBI) television networks ShopHQ, ShopHQHealth and ShopBulldogTV have become the first and only shopping television networks to offer an FDA-authorized, at-home COVID-19 test to consumers in the United States.

The Company’s ShopHQHealth television network is squarely focused on the growing $11 billion dollar U.S. Telehealth marketplace that offers consumers health-related products and services in their own homes via interactive video, delivered to them via a cable box, the Internet, over-the-top services like Apple TV, Roku or over-the-air services from broadcasters. 

The core customer in the Telehealth space is the same core customer iMedia interacts with today, men and women who are 45 and older. The Company believes the growth in this marketplace is being driven by consumers who are seeking to purchase an advanced level of health education, products and/or services at lower costs via interactive video in their own homes. Based on these characteristics, the Company believes it is strategically situated to capture a meaningful share of this growing marketplace.

The Company officially launched its COVID-19 test on live national television on January 2^nd with Dr. Terry Dubrow and broadcast it across its television networks and streamed across its associated websites and OTT Apps. iMedia is offering consumers a highly effective, Emergency Use Authorized (“EUA”), safe and reliable solution to help them combat the spread of COVID-19 from their own homes.

iMedia has partnered with Biotech Accelerated to facilitate and operate this testing program, along with P23 Labs as its FDA EUA authorized testing lab facility.

iMedia’s tests are saliva-based, rRT-PCR tests, which are the gold standard in molecular diagnostics and the most accurate type of test for COVID-19. iMedia is making it easy and affordable for its customers to test from their own homes and receive results within 48 hours.

A physician’s order is provided to the customer after a CDC-compliant health screening is completed. The collection device, which is overnighted to the lab after collection, inactivates the SARS-CoV-2 virus on contact, which makes the test safer for transport. Refrigerant or cold-chain processing is not required, which reduces the risk of false-negative test results. Results are then delivered through an encrypted portal via text and email. As part of the product, iMedia offer its customers a telemedicine medical review of the results with a healthcare professional.

Equally important, iMedia’s product offering qualifies for FSA/HSA reimbursement, and the results of these tests are maintained in a HIPAA-protected database through Curogram to ensure consumer privacy.

“As I have talked about since the launch of our ShopHQHealth TV network, these large, fast-growing telehealth marketplaces are important opportunities for us,” said Tim Peterman, CEO of iMedia Brands. “ShopHQHealth’s reason for being is to help consumers manage their health and wellness from their own homes. We are just getting started.”

About iMedia Brands, Inc.

iMedia Brands, Inc. (Nasdaq: IMBI) is a leading interactive media company that owns a growing portfolio of lifestyle television networks, consumer brands and media commerce services. Its brand portfolio spans multiple business models and product categories. Its television brands are ShopHQ, ShopBulldogTV, ShopHQHealth and LaVenta. Its media commerce services brands are Float Left Interactive and i3PL. Its consumer brands include J.W. Hulme, Live Fit and Indigo Thread. Please visit www.imediabrands.com for more investor information.

About Biotech Accelerated, LLC

Biotech Accelerated is a biotechnology company that strives to bring the best health technology to public and private communities locally and internationally. It is currently and actively delivering solutions for the COVID-19 Pandemic to corporations, governments, and individuals. Contact [email protected] with inquiries or visit biotechaccelerated.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This release contains statements, estimates, projections, guidance or outlooks that constitute “forward-looking” statements as defined under U.S. federal securities laws. Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “plan,” “project,” “should” and similar expressions identify forward-looking statements, which generally are not historical in nature. These statements may contain information about our prospects, including anticipated show, event, or product line launches, and involve risks and uncertainties. We caution that actual results could differ materially from those that management expects, depending on the outcome of certain factors.

Contacts:

Media:

[email protected]

(800) 938-9707

Investors:

Gateway Investor Relations
Cody Slach
[email protected]
(949) 574-3860

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced the launch of ProCBD™, a full product line of clinical strength CBD products available exclusively through health practitioners.

Clinical strength ProCBD™ products were created with the CV Sciences Medical Advisory Board specifically to meet patient needs and to fit seamlessly with existing care plans. ProCBD™ is the only CBD supported by published investigations, randomized controlled trial, and post marketing safety review.

Formulated with CV Sciences’ decarboxylated and distilled hemp extract for concentrated CBD levels that are best used under a specialist’s care, ProCBD™ is available in Roll-On, Liquids and Softgels. The ProCBD™ product line is non-GMO, gluten free, plant-based and vegan friendly.

“As the only clinical strength CBD on the market supported by multiple research studies, we believe ProCBD™ has tremendous potential in the professional healthcare channel,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “The use of alternative medicine is becoming increasingly prevalent as consumer preferences continue to shift toward natural, plant-based remedies for a range of medical conditions. We are excited to launch ProCBD™ and partner with medical professionals seeking science-based, natural alternatives to provide to their patients.”

About CV Sciences, Inc.

CV, or Curriculum Vitae, is Latin for “course of life”, and science is the pursuit of truth. CV Sciences: our name is our mission — improving quality of life through nature and science.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based dietary supplements and CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at more than 6,200 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry.  CV Sciences follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s products are processed, produced, and tested throughout the manufacturing process to confirm strict compliance with company standards and specifications.  With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov.  PlusCBD™ was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California.  Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
[email protected]

Media Contact:
ICR
Cory Ziskind
646-277-1232
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2e055ef7-e738-48a7-90a3-dfa536005a6a

VANCOUVER, British Columbia, Jan. 05, 2021 (GLOBE NEWSWIRE) — MOJAVE GOLD CORP. (CSE:MOJ) (OTCBB:MOJGF) (“Mojave” or the “Company”). The work completed during the month of December focused on several different priorities including stream sediment sampling, detailed geological mapping and chip sampling of mineralization. The stream sediment sampling campaign collected 261 samples dispersed throughout the entire 6000 ha property. Detailed geological mapping of two important mineralized zones (Sonora Cooper and Caracahui) was performed and included surface and underground mapping of existing adits. Combined, both zones comprise a roughly 60 ha area. Both areas display a series of veins and breccia structures that form an elongated feature that trends in a northeast-southwest direction.

Vein breccias have been mapped over several kilometers in length and are observed to obtain widths of several tens of meters. The Sonora Cooper West structure has been mapped for over 3km often reaching over 70m in width. In total, mineralized structures in the western part of the project area have been observed to extend more than 8.5 kilometers in cumulative length.

Detailed mapping at 1:1000 scale was completed over approximately 30 ha of the Sonora Cooper zone. The Sonora Cooper mineralized area contains large structures often reaching over 70m in width, that were mapped in detail for over 500m along strike. Additionally, detailed underground mapping was completed over 605m length in the Sonora Cooper adit and over a 260m length of the Guadalupe adit. A total of 160 rock chip samples were collected from the underground workings.

Approximately 20 ha of the Caracahui mineralized zone was mapped at 1:1000. Mojave geologists mapped breccia-vein structures and quartz veins averaging 1.5m in width for more than 400m along strike. Combined exposure length of the breccia-veins totals over 1000m. Preliminary analytical results indicate the vein-breccia sets are enriched in gold, copper and silver. A total of 139 rock chip samples were collected from the Caracahui mineralized zone.

Mojave geologists have reported the overall size of the structures and extent of associated mineralization is much larger and more pervasive than originally anticipated. Geologists also noted finding hereto unknown historical workings on the property. Mojave geologist Christian St. Clair reports, “Having boots on the ground has allowed us to focus in on the size of the structures at play and the unexpected extent of the associated mineralization. We look forward to receiving the analytical results from our first round of samples.”

Greg Bronson, CEO of Mojave states:

“The work completed so far tells us we are on the right track to find potential economic mineralization on the property. Mojave Gold Corp. is looking forward to receiving the first round of sample results and further exploring this very prospective property.”

FURTHER WORK PLANNED

Mojave geologists are anticipating analytical results from the stream sediment survey and will follow up newly highlighted of areas of interest.

Additional mapping is scheduled to take place between the Caracahui and Sonora Cooper mineralized areas to establish a geological connection between the zones.

Geologists will return to the Sonora Cooper zone to further map the northern part of the area and to rock chip sample the entire mapped area. While on location, geologists will complete the underground mapping and sampling of the Sonora Cooper and Guadalupe adits. Geologists are also scheduled to map and sample the Casabel adit.

The ongoing mapping of structure, rock type, alteration products and mineral assemblages will allow Mojave geologists to vector in on areas of enriched mineralization as our field work continues.

The company’s mandate is to leverage our strategic Mexican land portfolio and highly skilled talent pool into a class leading natural resource company committed to adhering to international operational and environmental standards in mining. Our success will deliver excellent value to all stakeholders including our partner communities, our employees, and investors.

Greg Bronson, P.Geo., has prepared, reviewed, and approved the scientific and technical information in this news release.

On behalf of the Board of Directors

“Greg Bronson” President / CEO Mojave Gold Corp.

[email protected]

www.mojavegoldcorp.com

Forward Looking Statements

Certain of the statements made and information contained herein may contain forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information includes, but is not limited to, information concerning the Company’s intentions with respect to the development of its mineral properties. Forward-looking information is based on the views, opinions, intentions and estimates of management at the date the information is made, and is based on a number of assumptions and subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated or projected in the forward-looking information (including the actions of other parties who have agreed to do certain things and the approval of certain regulatory bodies). Many of these assumptions are based on factors and events that are not within the control of the Company and there is no assurance they will prove to be correct. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by applicable securities laws, or to comment on analyses, expectations or statements made by third parties in respect of the Company, its financial or operating results or its securities. The reader is cautioned not to place undue reliance on forward-looking information. We seek safe harbour.

 

• Repayment provides greater operational flexibility to build on record cannabis revenue realized in Q4 2020
• Results in $2M reduction in annual interest payments

TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce its intention to repay in cash its 8% unsecured convertible debt (the “Convertible Debt”) which matures on February 2, 2021. The Convertible Debt was issued by Emblem Corp. on February 2, 2018, and Emblem was acquired by the Company on March 14, 2019.

The Company currently has no materially significant senior secured debt, and its facilities are fully unencumbered, providing further flexibility for additional financing if necessary. The repayment will result in a $2 million reduction in annual interest expenses.

“Through continued fiscal discipline over the course of 2020 and our focus on sustainable growth, we are in a position to eliminate near-term debt. We believe that this approach benefits shareholders and clears the path for continued growth in 2021,” said Aleafia Health CEO Geoffrey Benic.

“The path we’ve taken is now delivering clear results, achieving record cannabis revenue in our recently completed fourth quarter. We look forward to building on the quarter’s robust sales growth across every cannabis sales channel, including domestic medical, adult-use, wholesale, and international.”

For Investor & Media Relations:

Nicholas Bergamini, VP Investor Relations
1-833-879-2533
[email protected]
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.

Aleafia Health owns three significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.

Innovation, the heart of Aleafia Health’s competitive advantage, has led to the Company maintaining a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value; the TSX Venture Exchange named Aleafia the 2019 top performing company prior to its graduation to the TSX.

Forward Looking Information

This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) — Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary cannabinoid derived molecules to treat glaucoma and other diseases with significant unmet needs, announced today that Punit Dhillon, CEO, Emerald Bioscience will be presenting at the KCSA Cannabis Investor Conference on Thursday, January 7, 2021.

Presentation details are as follows:

Event: KCSA Cannabis Investor Conference
Presentation Date: Thursday, January 7, 2021
Presentation Time: 2:30 – 3:00 PM ET

This will be an interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event on the day of the conference, an archived webcast will be available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

For more information and/or to register for the conference please visit: https://bit.ly/3ngFk5v.

About Emerald Bioscience, Inc.

Emerald Bioscience Inc. is a biopharmaceutical company focused on the development of differentiated, proprietary cannabinoid derived molecules for the treatment of diseases with significant unmet needs. The company’s lead molecule, in preclinical studies, has demonstrated potential as a new class of therapy to lower intraocular pressure in patients with glaucoma or elevated intraocular pressure that is superior to currently available drugs. For more information, visit www.emeraldbio.life

CONTACT

Karam Takhar
VP, Corporate Development & Investor Relations
Email: [email protected]
Phone: +1-949-336-3437

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements regarding our product development, business strategy, relocation of corporate headquarters, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “contemplates,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Emerald may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Emerald’ most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Emerald disclaims any intent or obligation to update these forward-looking statements.

MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) — Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to announce that it has engaged Landon Capital to provide investor relations services effective December 30, 2020.  Services will include introductions to investors, financial and industry analysts, registered brokers and financial writers with a view to informing such groups about developments in the Company’s business and affairs. Landon Capital will assist to develop a database of individuals, financial institutions or other persons potentially interested in receiving publicly available information relating to the Company and making efforts to efficiently provide such information.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Landon Capital
Keith Pinder
(404) 995-667
[email protected]

 

TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) — Worksport Ltd (OTCQB: WKSP) (or the “Company”) is announcing that, to date, it has raised over US$1.1 Million from its Regulation A public offering. The offering can remain open until November 2021 but with over 25% of the target amount received, the Company believes that it will be closed ahead of schedule.

“The success of Worksport’s Regulation A offering has been very gratifying, and we wish to thank all those who expressed their faith in the Company’s future by investing in it,” said Worksport CEO Steven Rossi. “Its potential early closing is a testimony to the Company meeting the many milestones we have experienced since inception.”

Some of these milestones include:

	●	Intellectual Property Portfolio of over 30 patents and trademarks in the U.S., Canada, China, and globally
	●	Large private label customers purchasing volumes direct from Worksport but due to individual customization not in conflict with the Company’s own brand
	●	The TerraVis™ and Cor Battery System launch and development
	●	Initial TerraVis™ partnerships with Atlis and Hercules (in partnership with Nissan), two prominent forthcoming EV nameplates

“These accomplishments have been achieved with limited outside investment, while vigorously protecting the Company’s capital and equity treasury,” added Rossi. “We strongly believe in a successful future for Worksport, especially based upon our offering’s initial success. Worksport will be a lean and formidable force in the automotive markets, now with more free cash than ever before. We have shown just how far we can come with limited cash. Now we will show what is possible with incoming growth capital.”

The Regulation A proceeds will be directed to a number of key Worksport growth projects, the first of which is to fully launch all product lines and establish local Canadian manufacturing, Rossi said. Localized manufacturing will allow the Company produce orders “just in time” and begin expeditiously growing Worksport B2B and B2C revenue channels. The TerraVis Cor Battery System and the ground-breaking TerraVis^™ tonneau cover system, which integrate solar panels and battery banks for a mobile power solution, will be finalized and assembled in the proposed Ontario factory. Localized manufacturing will also allow the Company the flexibility to launch additional exciting projects that will be disclosed as they become finalized.

“We believe that the year ahead will be a transformative year for Worksport – we have a lot in store for our customers, shareholders, supporters, and investors,” Rossi said. “We have only just begun, and we always mean what we say and deliver on our promises. There is no bigger milestone than when a thriving business with a proven business model receives financing to both expedite and broaden its forward path to success. This closing of our first major financing round signifies a great start to the year ahead. As we work towards closing on the remaining US $3,000,000 in financing, we aim to exponentially grow while offering an exceptional value proposition to customers and investors alike.”

Worksport management will be disclosing details on plans for new projects as well as details on milestones relating to its conventional product lineup, and new team members in the near future.

Worksport’s Regulation A offering is still open at www.invest.worksport.com – any interested investors are encouraged to participate in this opportunity before it closes. Minimum investment is $500, and all securities purchased are registered and tradeable. Investors have an opportunity to purchase one common share and one 12-month warrant, directly from the Company. Investors are encouraged to view the company’s newest investor presentation at: https://presentation.worksport.com/

Any interested investors or shareholders are also encouraged to follow the company’s social media accounts on Twitter, Facebook, LinkedIn, and Instagram, as well as sign up for the company’s newsletters on both www.worksport.com and www.goterravis.com, to stay up to date on all of the latest news. Worksport will continue to update shareholders, supporters, and investors to maintain the highest level of disclosure and information dissemination as Worksport continues to grow and develop at a very rapid pace.

About Worksport Ltd.

Worksport Ltd., an innovative manufacturer of high quality, functional, and aggressively priced tonneau covers for light trucks like the F150, Sierra, Silverado, Canyon, RAM, and Ford F-Series. For more information, please visit www.worksport.com. Currently listed on the OTCQB Market under the trading symbol “WKSP.”

Connect with Worksport:

LinkedIn

Facebook

Twitter

Instagram

For further information please contact:

Mr. Steven Rossi
CEO & Director
Worksport, Ltd

T: 1-888-554-8789
E: [email protected]

Forward-Looking Statements

This document may contain forward-looking statements, relating to Worksport, Ltd. operations or to the environment in which it operates, which are based on Franchise Holdings International Inc. operations, estimates, forecasts and projections. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, and/or are beyond Worksport, Ltd.’s ’s control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. Consequently, readers should not place any undue reliance on such forward-looking statements. Worksport, Ltd. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No Stock Exchange or Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

WARSAW, Indiana, Jan. 05, 2021 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced the 510(k) approval, and limited U.S. launch of its first sterile-packed implants for the Pediatric Nailing Platform | FEMUR (“PNP|FEMUR”).

The PNP|FEMUR system, now available in 4 countries, was designed for use in pediatric patients to address femoral shaft fractures, subtrochanteric femur fractures, ipsilateral neck/shaft fractures, prophylactic nailing of impending pathologic fractures, nonunions, malunions, and fixation of femurs that have been surgically prepared (osteotomy) for correction of deformity. Worldwide, the PNP|FEMUR system has been used to treat over 1,000 children since its launch in 2018.

With the introduction of sterile nails, the next generation PNP|FEMUR system continues to add more options and new flexibility for surgeons and hospital systems. Now, the most comprehensive pediatric specific PNP|FEMUR implant offering will be made available sterile. The 510(k) clearance and availability of this implant helps hospitals improve patient safety and better trace implant usage while lowering Sterile Processing Departments’ turnover burden and costs.

Joe Hauser, OrthoPediatrics’ Vice President of Trauma & Deformity Correction, stated, “The introduction of sterile implants represents an important addition to our portfolio of sterile implant offerings. We are committed to adding sterile implants to the systems that can provide real value to our customers. We are strategically aligned with our customers to decrease the overall footprint of all our systems while balancing and ensuring intraoperative efficiency.”

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 35 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 43 countries outside the United States. For more information, please visit www.orthopediatrics.com.

Investor Contact

The Ruth Group
Jan Medina, CFA
(646) 536-7035
[email protected]

WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021.

Details of the events are as follows:

• 10^th Annual LifeSci Partners Corporate Access Event: The company will host virtual one-on-one meetings during the conference on Wednesday, January 6 through Friday, January 8 and Monday, January 11 through Thursday, January 14, 2021.
• H.C. Wainwright Virtual BioConnect Conference: The company’s presentation will be available for on-demand viewing on Mustang’s website beginning Monday, January 11, 2021, at 6:00 a.m. EST.
• B. Riley Securities’ Virtual Oncology Investor Conference: The company’s presentation will take place on Thursday, January 21, 2021, at 1:30 p.m. EST and will be available to all conference-registered institutional investors.

Webcasts of the H.C. Wainwright and B. Riley presentations will be available on the Events page of the Investors Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days following each presentation.

About Mustang Bio

Mustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com.

Forward‐Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contacts:

Jaclyn Jaffe and William Begien
Mustang Bio, Inc.
(781) 652-4500
[email protected]

Investor Relations Contact:

Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
[email protected]

Media Relations Contact:

Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]